Episode 73: Genentech's Quita Highsmith
from The Refill, by MM+M Hosted by The MM+M Podcast
Genentech isn’t currently developing a SARS-CoV-2 vaccine or therapeutic, but the biotech has been conducting research that could bring insight to bear on the willingness among communities of color to engage in clinical trials for COVID-19 vaccines and treatments. Quita Highsmith, Genentech’s chief diversity officer, speaks about that, and the biotech’s own efforts to recruit and instill more trust among underserved and medically disenfranchised patients. Is your team still treating AI like a side experiment while competitors use it to win? Cut through the buzzword fatigue. On November 12th, join hundreds of top marketers in New York City for AI Deciphered, presented by Campaign, MM+M, and PRWeek. Get real-world playbooks from leaders like Reddit’s Rob Gaige and Yahoo’s Matt Sanchez across dedicated tracks built for daily execution. Check us out at: mmm-online.com Follow us: YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Embed this episode
What this episode covers
Genentech isn’t currently developing a SARS-CoV-2 vaccine or therapeutic, but the biotech has been conducting research that could bring insight to bear on the willingness among communities of color to engage in clinical trials for COVID-19 vaccines and treatments. Quita Highsmith, Genentech’s chief diversity officer, speaks about that, and the biotech’s own efforts to recruit and instill more trust among underserved and medically disenfranchised patients.
No transcript yet.